Ultragenyx Pharmaceutical Inc. $RARE Stock Sold by Privium Fund Management B.V.

Privium Fund Management B.V. trimmed its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 31.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 233,037 shares of the biopharmaceutical company’s stock after selling 105,763 shares during the period. Ultragenyx Pharmaceutical accounts for approximately 0.7% of Privium Fund Management B.V.’s investment portfolio, making the stock its 28th biggest position. Privium Fund Management B.V.’s holdings in Ultragenyx Pharmaceutical were worth $3,503,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Parallel Advisors LLC lifted its stake in Ultragenyx Pharmaceutical by 778.4% in the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 1,440 shares during the last quarter. Sterling Capital Management LLC increased its stake in shares of Ultragenyx Pharmaceutical by 102.4% during the 3rd quarter. Sterling Capital Management LLC now owns 2,475 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 1,252 shares during the last quarter. Versant Capital Management Inc increased its stake in shares of Ultragenyx Pharmaceutical by 662.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 1,001 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 573.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 1,845 shares during the period. Finally, Quantbot Technologies LP bought a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at about $48,000. 97.67% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,066 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $15.27, for a total value of $107,897.82. Following the transaction, the chief financial officer directly owned 89,229 shares of the company’s stock, valued at $1,362,526.83. This represents a 7.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 8,510 shares of company stock valued at $127,561. 5.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on RARE shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, October 6th. UBS Group started coverage on Ultragenyx Pharmaceutical in a research report on Thursday, October 15th. They set a “neutral” rating and a $16.00 price target on the stock. Evercore lowered Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 price objective on the stock. in a research note on Thursday, September 3rd. Wells Fargo & Company raised their price objective on Ultragenyx Pharmaceutical from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Wednesday. Finally, Cantor Fitzgerald raised their price objective on Ultragenyx Pharmaceutical from $33.00 to $39.00 and gave the company an “overweight” rating in a research report on Friday, September 18th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of “Hold” and a consensus price target of $29.79.

Check Out Our Latest Report on RARE

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

  • Positive Sentiment: The UK medicines regulator has accepted Ultragenyx’s marketing application for rebi-vec (UX111), its gene therapy for Sanfilippo syndrome Type A, and is reviewing it. This is a step toward a possible UK authorization, but the therapy remains investigational and has not been approved. Company announcement
  • Positive Sentiment: H.C. Wainwright and TD Cowen both reiterated Buy ratings, signaling that these analysts see potential despite recent price-target reductions. H.C. Wainwright rating TD Cowen rating
  • Negative Sentiment: Several firms have lowered their price targets, reflecting more restrained expectations. Canaccord cut its target from $39 to $34, Citi reduced its target from $32 to $22, and Barclays lowered its target from $35 to $32; all retained Buy or Overweight ratings. The revisions may weigh on sentiment even as analysts remain positive on the shares. Canaccord target revision Citi target revision

Ultragenyx Pharmaceutical Trading Down 0.9%

Shares of NASDAQ:RARE traded down $0.14 on Friday, hitting $15.43. The company had a trading volume of 4,049,110 shares, compared to its average volume of 3,379,657. The stock has a market cap of $1.52 billion, a price-to-earnings ratio of -2.97 and a beta of 0.37. The stock has a 50 day moving average price of $16.02 and a 200 day moving average price of $22.71. Ultragenyx Pharmaceutical Inc. has a 1-year low of $12.73 and a 1-year high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.06). The firm had revenue of $173.00 million for the quarter, compared to the consensus estimate of $182.49 million. The business’s revenue was up 8.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.81) EPS. Sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -3.45 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Profile

(Free Report)

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.

Featured Stories

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.